NCT06270108

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 288 (estimated)
• Sponsor: King's College London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this basic science study is to to explore the responsivity of glutamate in the brain of treatment-resistant schizophrenia patients to the drug riluzole. The main aims of the study are: To assess the role of glutamate in treatment-resistant schizophrenia using magnetic resonance spectroscopy. To assess the relationship between glutamate levels and brain structural and functional measures (using: structural MRI; functional MRI (fMRI) and arterial spin labelling (ASL)) at baseline. To assess the relationship between longitudinal change in glutamate levels and brain structural and functional measures. To assess the relationship between longitudinal change in glutamate levels and changes in psychopathology. The researchers will compare the changes with healthy controls and those without treatment-resistant schizophrenia.

Conditions

• Treatment-resistant Schizophrenia
• Treatment-responsive Schizophrenia
• Healthy Controls

Interventions

Type	Name	Description
DRUG	Riluzole	50mg twice daily (100mg total daily) for 56 days.

Timeline

• Start date: 2022-11-14
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2024-02-21
• Last updated: 2024-03-05

Locations

1 site across 1 country: United Kingdom